Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Explore linked clinical trials.16 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-28 | NCT07844187 | |
| A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors | Advanced Malignancies | Recruiting | Phase 1 | 2026-09-15 | NCT07730190 | |
| Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers | Advanced Cancers | Recruiting | Phase 1 | 2026-09-10 | NCT07260708 | |
| A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects. | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 1 | 2026-08-31 | NCT07794111 | |
| TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-08-19 | NCT06829784 | |
| Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-25 | NCT07385703 | |
| Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) | Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | Phase 3 | 2026-05-29 | NCT07165951 | |
| Treatment of Recurrent/Metastatic Head and Neck Cancer | Head and Neck Neoplasms, Neoplasms by Site, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-22 | NCT07601204 | |
| Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients | Systemic Light Chain Amyloidosis | Recruiting | Phase 1 / Phase 2 | 2026-05-08 | NCT07266116 | |
| To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 3 | 2026-04-20 | NCT06552520 | |
| Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis | Hypersensitivity, Immediate, Respiratory Hypersensitivity, Rhinitis, Allergic, immune system disorder, nasal disorder, otorhinolaryngologic disease, respiratory system disorder, rhinitis, seasonal allergic rhinitis | Recruiting | Phase 2 | 2026-03-27 | NCT07398859 | |
| Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Recruiting | Phase 3 | 2025-12-16 | NCT07107256 | |
| A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2025-12-12 | NCT06707883 | |
| Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 3 | 2025-09-23 | NCT07187960 | |
| Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies | CD20-positive Hematological Malignancies | Not yet recruiting | Phase 1 | 2025-08-07 | NCT07110194 | |
| Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-03-24 | NCT06854445 |